Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 2/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 6/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8471852 | 1.00 | PDE7A (0.48) | PDE7AAKR1B1HTR6IDO1MMP2 | |
| SCHEMBL1408090 | 1.00 | PDE7A (0.48) | PDE7AAKR1B1HTR6IDO1MMP2 | |
| SCHEMBL21940203 | 0.86 | PDE7A (0.50) | PDE7AAKR1B1HTR6IDO1AKR1A1 | |
| SCHEMBL6853497 | 0.83 | MMP2 (0.40) | PDE7AAKR1B1HTR6MMP2MMP9 | |
| SCHEMBL6853499 | 0.76 | PDE7A (0.46) | PDE7AAKR1B1IDO1AKR1A1PGR | |
| SCHEMBL5479245 | 0.74 | CHRM2 (0.62) | PDE7AAKR1B1HTR6IDO1PSEN1 | |
| SCHEMBL21939601 | 0.70 | IDO1 (0.40) | PDE7AAKR1B1HTR6IDO1MMP2 | |
| SCHEMBL21939542 | 0.70 | AKR1B1 (0.46) | PDE7AAKR1B1MMP2MMP9LRRK2 | |
| SCHEMBL19605042 | 0.70 | AKR1B1 (0.46) | PDE7AAKR1B1MMP2MMP9LRRK2 | |
| SCHEMBL542817 | 0.69 | LMNA (0.51) | AKR1B1HTR6MMP2MMP9AKR1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9872858-B2 | Treatment of degenerations and light-induced damage to the retina | BIOCODEX (FR) | 2018-01-23 | — | — | US | disclosed |
| US-9872858-B2 | Treatment of degenerations and light-induced damage to the retina | BIOCODEX (FR) | 2018-01-23 | — | — | US | disclosed |
| US-20170000798-A1 | TREATMENT OF DEGENERATIONS AND LIGHT-INDUCED DAMAGE TO THE RETINA | BIOCODEX (FR) | 2017-01-05 | — | — | US | disclosed |
| US-20170000798-A1 | TREATMENT OF DEGENERATIONS AND LIGHT-INDUCED DAMAGE TO THE RETINA | BIOCODEX (FR) | 2017-01-05 | — | — | US | disclosed |
| US-8338410-B2 | Neuroprotective compounds and pharmaceutical compositions comprising them | BIOCODEX (FR) | 2012-12-25 | — | — | US | disclosed |
| US-8338410-B2 | Neuroprotective compounds and pharmaceutical compositions comprising them | BIOCODEX (FR) | 2012-12-25 | — | — | US | disclosed |
| WO-2012120423-A1 | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCERS | BIOCODEX (FR) | 2012-09-13 | — | — | WO | disclosed |
| EP-1745785-B1 | Pharmaceutical composition for preventing or treating cerebral oedema | BIOCODEX (FR) | 2011-03-09 | — | — | EP | disclosed |
| US-20090298817-A1 | ANTI-AMNESIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | BIOCODEX (FR) | 2009-12-03 | — | — | US | disclosed |
| US-20090298817-A1 | ANTI-AMNESIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | BIOCODEX (FR) | 2009-12-03 | — | — | US | disclosed |
| US-7569565-B2 | Etifoxine derivatives; corticoids; methyl-d-aspartic acid antagonists | BIOCODEX (FR) | 2009-08-04 | — | — | US | disclosed |
| US-7569565-B2 | Etifoxine derivatives; corticoids; methyl-d-aspartic acid antagonists | BIOCODEX (FR) | 2009-08-04 | — | — | US | disclosed |
| US-20070167446-A1 | Neuroprotective compounds and pharmaceutical compositions comprising them | BIOCODEX (FR) | 2007-07-19 | — | — | US | disclosed |
| US-20070167446-A1 | Neuroprotective compounds and pharmaceutical compositions comprising them | BIOCODEX (FR) | 2007-07-19 | — | — | US | disclosed |
| US-20070021415-A1 | Pharmaceutical composition for the prevention or treatment of cerebral oedemas | BIOCODEX (FR) | 2007-01-25 | — | — | US | disclosed |
| US-20070021415-A1 | Pharmaceutical composition for the prevention or treatment of cerebral oedemas | BIOCODEX (FR) | 2007-01-25 | — | — | US | disclosed |
| EP-1745786-A1 | Neuroprotective compounds and pharmaceutical compositions comprising them | Biocodex (FR) | 2007-01-24 | — | — | EP | disclosed |
| EP-1745785-A1 | Pharmaceutical composition for preventing or treating cerebral oedema | Biocodex (FR) | 2007-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167446-A1 | Neuroprotective compounds and pharmaceutical compositions comprising them | BDNF, NLN, GAP43 | PDE7A 3109/4885AKR1B1 1998/4885HTR6 613/4885 |
| US-20170000798-A1 | TREATMENT OF DEGENERATIONS AND LIGHT-INDUCED DAMAGE TO THE RETINA | ALDH1A2, ALDH1A3, PDE6D | PDE7A 1432/4885AKR1B1 635/4885HTR6 3808/4885 |
| US-20090298817-A1 | ANTI-AMNESIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | GRIK5, GRIN2C, GRIN3B | PDE7A 663/4885AKR1B1 1928/4885HTR6 296/4885 |
| US-20070021415-A1 | Pharmaceutical composition for the prevention or treatment of cerebral oedemas | AQP4, AQP1, AQP3 | PDE7A 913/4885AKR1B1 849/4885HTR6 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.